OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects

NCT ID: NCT00902837

Last Updated: 2018-10-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

181 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-05-31

Study Completion Date

2010-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objectives are

* to demonstrate that the treatment with OXN PR tablets is non-inferior to the treatment with OxyPR with regards to analgesic efficacy and locomotor function.
* to demonstrate that subjects with moderate to severe OA pain taking oxycodone/naloxone prolonged release tablets have improvement in symptoms of constipation compared to subjects taking oxycodone prolonged release tablets alone

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects with moderate to severe pain due to osteoarthritis (OA) will be randomised to oxycodone/naloxone prolonged release (OXN PR) or oxycodone prolonged release tablets (OxyPR) alone to demonstrate that the treatment with OXN PR tablets is non-inferior to the treatment with OxyPR with regards to analgesic efficacy and locomotor function and to demonstrate that subjects taking OXN PR have improvement in symptoms of constipation compared to subjects taking OxyPR alone.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

oxycodone Tablet

OxyCodone Prolonged release tablets

Group Type ACTIVE_COMPARATOR

oxycodone prolonged release tablet

Intervention Type DRUG

oxycodone naloxone tablet

Oxycodone naloxone prolonged release tablets (OXN)

Group Type EXPERIMENTAL

Oxycodone naloxone prolonged release tablets (OXN)

Intervention Type DRUG

oxycodone naloxone tablet

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oxycodone naloxone prolonged release tablets (OXN)

Intervention Type DRUG

oxycodone prolonged release tablet

Intervention Type DRUG

oxycodone naloxone tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Moderate to severe chronic nonmalignant OA and that require around-the-clock opioid therapy.

Exclusion Criteria

* Females who are pregnant or lactating.
* Subjects with evidence of significant structural abnormalities of the gastrointestinal tract.
* Subjects with evidence of impaired liver/kidney function upon entry into the study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mundipharma Research GmbH & Co KG

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ghent, , Belgium

Site Status

Dr R Flasar

Brno, , Czechia

Site Status

FN U Svate Anny

Brno, , Czechia

Site Status

Urazova nemocnice v Brne

Brno, , Czechia

Site Status

Dr E Lengalove

České Budějovice, , Czechia

Site Status

Dr M Vdoviak

Karlovy Vary, , Czechia

Site Status

Nemocnice Most

Most, , Czechia

Site Status

Fakultni nemocnice Olomouc

Olomouc, , Czechia

Site Status

Plzen-Lochotin, , Czechia

Site Status

Revmatologicka ambulance

Prague, , Czechia

Site Status

VFN Praha

Prague, , Czechia

Site Status

Dr Z Urbanova

Prague, , Czechia

Site Status

Revmatologicka ambulance

Prague, , Czechia

Site Status

Chirurgicke oddeleni

Prague, , Czechia

Site Status

FN Na Bulovce

Prague, , Czechia

Site Status

Revmatologicka ambul

Uherské Hradiště, , Czechia

Site Status

Kuopio, , Finland

Site Status

Dr I Palutke

Bad Klosterlausnitz, , Germany

Site Status

Dr G Voss

Berlin, , Germany

Site Status

Schmerzzentrum Celle

Celle, , Germany

Site Status

Dr S Grunert

Eichstätt, , Germany

Site Status

Gemeinschaftspraxis fuer

Greifswald, , Germany

Site Status

Clinical Research

Hamburg, , Germany

Site Status

Praxis fur klinische Studien

Hamburg, , Germany

Site Status

Dr E A Lux

Lünen, , Germany

Site Status

Dr O Lowenstein

Mainz, , Germany

Site Status

Dr U Schutter

Marl, , Germany

Site Status

Dr H M Frick

Rhaunen, , Germany

Site Status

Prof Dr F Weber

Senftenberg, , Germany

Site Status

Senftenberg, , Germany

Site Status

Dr U Krauspe

Weimar, , Germany

Site Status

Dr J Hafer

Wetzlar, , Germany

Site Status

Intermed Institue fur Medizinische Forschung & Arzneimittelsicherheit

Wiesbaden, , Germany

Site Status

Schmerz und Palliativzentrum

Wiesbaden, , Germany

Site Status

Mezőkövesd, , Hungary

Site Status

Madrid, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Czechia Finland Germany Hungary Spain

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2008-002670-36

Identifier Type: -

Identifier Source: secondary_id

OXN3503

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Opioid-Sparing Joint Replacement
NCT07348627 NOT_YET_RECRUITING PHASE3
Opioids Following ACL
NCT04278703 UNKNOWN NA
ACL-R Opioid Sparing Study
NCT06561035 ENROLLING_BY_INVITATION PHASE3
A Study of Pain Relief in Osteoarthritis
NCT00298974 COMPLETED PHASE3